Results 161 to 170 of about 73,730 (304)
Abstract Objectives This paper aims to describe the treatment patterns of contemporary systemic menopausal hormone therapy (MHT) in Denmark. Study design This study is a nationwide drug utilization study including an open cohort of all Danish women aged >40 years between 2000–2024.
Hannah K. Wood‐Kurland +7 more
wiley +1 more source
Abstract Cyclizine is a long‐established, short‐acting drug, registered for preventing motion sickness, post‐operative nausea and vomiting (PONV) and ‘vomiting of known cause’. The latter is not defined but may include pregnancy and patients receiving palliative care, historically accepted without large, controlled trials.
Gareth J. Sanger, Paul L. R. Andrews
wiley +1 more source
Insights into Neanderthal development, childbirth, and locomotion from the Palomas and Dederiyeh pelves. [PDF]
Zollikofer CPE +7 more
europepmc +1 more source
MiR‐29b is enriched in extracellular vesicles (EVs) via a tetraspanin transporter‐dependent endocytosis and sorting complex required for the endosomal transport (ESCRT)‐dependent pathway. These EVs target the 3′ untranslated region (3′UTR) of TGFB2, thereby inhibiting the TGF‐β/Smad3 signaling pathway and repairing endometrial damage in intrauterine ...
Lihao Chen +10 more
wiley +1 more source
Female genital mutilation/cutting and obstetrical anal sphincter injury risk in the United States. [PDF]
Stirling-Cameron E, Perry C, Stairs J.
europepmc +1 more source
As use cases for long‐acting therapeutics expand across clinical indications, there is a critical need to ensure the inclusion of women who are pregnant or breastfeeding, infants and children—populations with a historical gap in the availability of interventions already approved for use in adults.
Moherndran Archary +59 more
wiley +1 more source
Society for Maternal-Fetal Medicine Special Statement: Checklist for initial management of amniotic fluid embolism-Updated 2026. [PDF]
Society for Maternal‐Fetal Medicine (SMFM) +6 more
europepmc +1 more source
Pregnancy‐associated breast cancer (PrBC) presents therapeutic challenges. Understanding maternal–fetal safety of systemic anticancer therapies is critical. We performed a case/non‐case disproportionality analysis using the WHO global pharmacovigilance database up to January 2024, to evaluate maternal–fetal outcomes associated with breast cancer (BC ...
Rayan Kabirian +12 more
wiley +1 more source

